Vaccine allergy: Diagnosis and management

Immunology and Allergy Clinics of North America

Volumn 23, Issue 4, 2003, Pages 555-588

  Madaan, Arvind ^a   Maddox, Daniel E ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX VACCINE; ANTIBIOTIC AGENT; BIAVAX II; CHICKENPOX VACCINE; CHOLERA VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TETANUS TOXOID; DIPLOID CELL VACCINE; EGG PROTEIN; GELATIN; HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS A HEPATITIS B VACCINE; HEPATITIS A VACCINE; INACTIVATED VACCINE; INFLUENZA VACCINE; IPOL; JAPANESE ENCEPHALITIS VACCINE; LIQUID PEDVAXHIB; LIVE VACCINE; LYME DISEASE VACCINE; M R VAX II; MEASLES MUMPS RUBELLA VACCINE; MEASLES VACCINE; MENINGOCOCCUS VACCINE; MMR II; MUMPS VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; POLYSACCHARIDE VACCINE; RABIES VACCINE; RECOMBINANT HEPATITIS B VACCINE; RUBELLA VACCINE; TETANUS TOXOID; TOXOID; TRIHIBIT; TYPHOID VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE; YELLOW FEVER VACCINE;

ABSCESS; ALLERGIC DISEASE; ANAMNESIS; ANAPHYLAXIS; ANOREXIA; ARTHRITIS; ASEPTIC MENINGITIS; BRACHIALGIA; BRAIN DISEASE; CARPAL TUNNEL SYNDROME; CLINICAL TRIAL; CRANIAL NERVE PARALYSIS; CRYING; DELAYED HYPERSENSITIVITY; DEMYELINATING DISEASE; DESENSITIZATION; DIAGNOSTIC TEST; DROWSINESS; DRUG CHOICE; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EGG ALLERGY; ERYTHEMA MULTIFORME; FATIGUE; FEBRILE CONVULSION; FEVER; FLU LIKE SYNDROME; GAIT DISORDER; GUILLAIN BARRE SYNDROME; HEADACHE; HEMOLYTIC ANEMIA; HERPES ZOSTER; HORNER SYNDROME; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNE DEFICIENCY; IMMUNIZATION; INFECTION; INFERTILITY; INJECTION PAIN; INSULIN DEPENDENT DIABETES MELLITUS; IRRITABILITY; JUVENILE DIABETES MELLITUS; KIDNEY FAILURE; LEARNING DISORDER; MALAISE; MONONEUROPATHY; MULTIPLE SCLEROSIS; MUSCLE HYPOTONIA; MYELITIS; MYOSITIS; NAUSEA; NERVOUS SYSTEM INJURY; NEURITIS; OPTIC NERVE DISEASE; ORCHITIS; PARESTHESIA; PAROTITIS; PERCEPTION DEAFNESS; PERIPHERAL NEUROPATHY; PHYSICAL EXAMINATION; POLIOMYELITIS; PRIORITY JOURNAL; PRURITUS; RASH; RETINOPATHY; REVIEW; SEIZURE; SERUM SICKNESS; SIDE EFFECT; SKIN TEST; SORE THROAT; SUBACUTE SCLEROSING PANENCEPHALITIS; SUDDEN INFANT DEATH SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; THROMBOCYTOPENIC PURPURA; URTICARIA; VASCULITIS; VOMITING;

EID: 0346733045     PISSN: 08898561     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8561(03)00099-7     Document Type: Review

References (67)

1. Crockett RE, Lockey RF. Vaccine hypersensitivity. Immunol Allergy Clin North Am 2001;21: 707-43.
2. Gellin BG, Maibach EW, Marcuse EK. Do parents understand immunizations? A national telephone survey. Pediatrics 2000;106(5):1097-102.
3. Stratton K, Wilson CB, McCormick MC. Executive summary: immunization safety review: multiple immunizations and immune dysfunction. Washington, DC: National Academy Press; 2002. p. 1-22.
4. Howson CP, Howe CJ, Fineberg HV. Adverse effects of pertussis and rubella vaccines. Washington, DC: National Academy Press; 1991.
5. Centers for Disease Control and Prevention. National Childhood Vaccine Injury Act: requirements for permanent vaccination records and for reporting of selected events after vaccination. MMWR Morb Mortal Wkly Rep 1988;37:197-200.
6. Stratton K, Howe CJ, Johnston Jr RB. Immunologic reactions. In: Adverse events associated with childhood vaccines: evidence bearing on casuality. Washington, DC: National Academy Press; 1994. p. 59-66.
7. Coombs R, Gell PG. Classification of allergic reactions responsible for clinical hypersensitivity and disease. In: Gell P, Coombs RR, Lachman PJ, editors. Clinical aspects of immunology. Oxford, UK: Blackwell Scientific Publications; 1975. p. 761.
8. US Department of Health and Human Services. National Childhood Vaccine Injury Act. Vaccine Injury Table (effective August 26, 2002). Available at: http://www.hrsa.gov/osp/vicp/table.htm.
9. Borgono JM, McLean AA, Vella PP, et al. Vaccination and revaccination with polyvalent pneumococcal polysaccharide vaccines in adults and infants (40010). Proc Soc Exp Biol Med 1978;157:148-54.
10. American Academy of Pediatrics. Active and passive immunization. In: Pickering LK, editor. 2000 Red book: report of the committee on infectious diseases. 25th edition. Elk Grove Village (IL): American Academy of Pediatrics Publications; 2003. p. 46-9.
11. Physicians' Desk Reference. 57th edition. Montvale (NJ): Medical Economics; 2003.
12. James JM, Burks AW, Roberson PK, et al. Safe administration of the measles vaccine to children allergic to eggs. N Engl J Med 1995;332:1262-6.
13. James JM, Zeiger RS, Lester MR, et al. Safe administration of influenza vaccine to patients with egg allergy. J Pediatr 1998;133:624-8.
14. Aukrust L, Almeland TL, Refsum D, et al. Severe hypersensitivity or intolerance reactions to measles vaccine in six children. Allergy 1980;35:581-7.
15. Herman JJ, Radin R, Schneiderman R. Allergic reactions to measles (rubeola) vaccine in patients hypersensitive to egg protein. J Pediatr 1983;102:196-9.
16. McEwen J. Early-onset reaction after measles vaccination. Med J Aust 1983;2:503-5.
17. Miller JR, Orgel A, Meltzer EO. The safety of egg-containing vaccines for egg-allergic patients. J Allergy Clin Immunol 1983;71:568-73.
18. Van Asperen PP, McEniery J, Kemp AS. Immediate reactions following live attenuated measles vaccine. Med J Aust 1981;2:330-1.
19. Zeiger RS. Current issues with influenza vaccination in egg allergy. J Allergy Clin Immunol 2002; 110:834-40.
20. Bridges CB, Fukuda K, Uyeki TM, Cox NJ, Singleton JA. Prevention and control of influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2002;51:1-31.
21. Khakoo GA, Lack G. Guidelines for measles vaccination in egg-allergic children. Clin Exp Allergy 2000;30:288-93.
22. Kelso JM. Raw egg allergy-A potential issue in vaccine allergy [letter]. J Allergy Clin Immunol 2000;106:990.
23. Businco L. Measles, mumps, rubella immunization in egg-allergic children: a long-lasting debate. Ann Allergy 1994;72:1-3.
24. Cantani A, Serra A, Arcese G, et al. Allergic reactions to MMR vaccines in egg- and non-egg-sensitive children: a continuing controversy. Pediatr Asthma Allergy Immunol 1995;9:7-14.
25. Pool V, Braun MM, Kelso JM, et al. Prevalence of anti-gelatin antibodies in people with anaphylaxis after measles-mumps-rubella vaccine in the United States. Pediatrics 2002;110:e71.
26. Kelso JM, Jones RT, Yunginger JW. Anaphylaxis to measles, mumps, and rubella vaccine mediated by IgE to gelatin. J Allergy Clin Immunol 1993;91:867-72.
27. Kumagai T, Ozaki T, Kamada M, et al. Gelatin-containing diphtheria-tetanus-pertussis (DTP) vaccine causes sensitization to gelatin in the recipients. Vaccine 2000;18:1555-61.
28. Sakaguchi M, Nakayama T, Inouye S. Food allergy to gelatin in children with systemic immediate-type reactions, including anaphylaxis, to vaccines. J Allergy Clin Immunol 1996;98:1058-61.
29. Sakaguchi M, Ogura H, Inouye S. IgE antibody to gelatin in children with immediate-type reactions to measles and mumps vaccines. J Allergy Clin Immunol 1995;96:563-5.
30. Sakaguchi M, Yamanaka T, Ikeda K, et al. IgE-mediated systemic reactions to gelatin included in the varicella vaccine. J Allergy Clin Immunol 1997;99:263-4.
31. Sakaguchi M, Inouye S. Two patterns of systemic immediate-type reactions to Japanese encephalitis vaccines. Vaccine 1998;16:68-9.
32. Nakayama T, Aizawa C, Kuno-Sakai H. A clinical analysis of gelatin allergy and determination of its causal relationship to the previous administration of gelatin-containing acellular pertussis vaccine combined with diphtheria and tetanus toxoids. J Allergy Clin Immunol 1999;103:321-5.
33. Singer S, Johnson CE, Mohr R, Holowecky C. Urticaria following varicella vaccine associated with gelatin allergy. Vaccine 1999;17:327-9.
34. Patja A, Mäkinen-Kiljunen S, Davidkin I, Paunio M, Peltola H. Allergic reactions to measles-mumps-rubella vaccination. Pediatrics 2001;107:e27.
35. Sakaguchi M, Nakayama T, Fujita H, Toda M, Inouye S. Minimum estimated incidence in Japan of anaphylaxis to live virus vaccines including gelatin. Vaccine 2000;19:431-6.
36. Nakayama T, Aizawa C. Change in gelatin content of vaccines associated with reduction in reports of allergic reactions. J Allergy Clin Immunol 2000;106:591-2.
37. Nakayama T, Aizawa C, Kuno-Sakai H. A clinical analysis of gelatin allergy and determination of its causal relationship to the previous administration of gelatin-containing acellular pertussis vaccine combined with diphtheria and tetanus toxoids. J Allergy Clin Immunol 1999; 103:321-5.
38. Sakaguchi M, Inouye S. IgE sensitization to gelatin: The probable role of gelatin-containing diphtheria-tetanus-acellular pertussis (DTaP) vaccines. Vaccine 2000;18:2055-8.
39. Kelso JM. The gelatin story. J Allergy Clin Immunol 1999;103:200-2.
40. Taniguchi K, Fujisawa T, Ihara T, et al. Gelatin-induced T-cell activation in children with non-anaphylactic-type reactions to vaccines containing gelatin. J Allergy Clin Immunol 1998;102: 1028-32.
41. Kumugai T, Yamanaka T, Wataya Y, et al. Gelatin-specific humoral and cellular immune responses in children with immediate- and non-immediate-type reactions to live measles, mumps, rubella, and varicella vaccines. J Allergy Clin Immunol 1997;100:130-4.
42. H2 cells in immediate and non-immediate reactions to gelatin-containing vaccine. J Allergy Clin Immunol 1999;103:276-81.
43. Miyazawa H, Saitoh S, Kumagai T, et al. Specific IgG to gelatin in children with systemic immediate- and nonimmediate-type reactions to measles, mumps and rubella vaccines. Vaccine 1999;17:2176-80.
44. Katz SL. Safety of measles vaccine in egg-sensitive individuals [reply]. J Pediatr 1978;92:859.
45. Schäfer T, Enders F, Przybilla B. Sensitization to thimerosal and previous vaccination. Contact Dermatitis 1995;32:114-6.
46. Tosti A, Guerra L, Bardazzi F. Hyposensitizing therapy with standard antigenic extracts: an important source of thimerosal sensitization. Contact Dermatitis 1989;20:173-6.
47. Tosti A, Melino M, Bardazzi F. Systemic reactions due to thimerosal. Contact Dermatitis 1986;15: 187-8.
48. Goodwin H, Nash M, Gold M, et al. Vaccination of children following a previous hypotonic-hyporesponsive episode. J Paediatr Child Health 1999;35:549-52.
49. Offit PA. Preventing harm from thimerosal in vaccines [letter]. JAMA 2000;283:2104-5.
50. Rietschel RL. Neomycin sensitivity and the MMR vaccine [letter]. JAMA 1981;245:571.
51. Kwittken PL, Rosen S, Sweinberg SK. MMR vaccine and neomycin allergy [letter]. Am J Dis Child 1993;147:128-9.
52. Watson JC, Peter G. General immune practices. In: Plotkin SA, Orenstein WA, editors. Vaccines. 3rd edition. Philadelphia: WB Saunders; 1999. p. 47-73.
53. Slater JE, Latex allergy. J Allergy Clin Immunol 1994;94:139-49.
54. Howson CP, Howe CJ, Fineberg HV. Adverse effects of pertussis and rubella vaccines. Washington, DC: Institute of Medicine, National Academy Press; 1991.
55. Slater DN, Underwood JCE, Durrant TE, et al. Aluminum hydroxide granulomas: light and electron microscopic studies and x-ray microanalysis. Br J Dermatol 1982;107:103-8.
56. Veien NK, Hattel T, Justesen O, et al. Aluminum allergy. Contact Dermatitis 1986;15:295-7.
57. Mark A, Björkstén B, Granström M. Immunoglobulin E responses to diphtheria and tetanus toxoids after booster with aluminum-adsorbed and fluid DT-vaccines. Vaccine 1995;13:669-73.
58. Sato Y, Kimura M, Fukumi H. Development of a pertussis component vaccine in Japan. Lancet 1984;1:122-6.
59. Mark A, Granström M. The role of aluminum for adverse reactions and immunogenicity of diphtheria-tetanus booster vaccine. Acta Paediatr 1994;83:159-63.
60. Relyveld EH, Bizzini B, Gupta RK. Rational approaches to reduce adverse reactions in man to vaccines containing tetanus and diphtheria toxoids. Vaccine 1998;16:1016-23.
61. Mansfield LE, Ting S, Rawls DO, et al. Systemic reactions during cutaneous testing for tetanus toxoid hypersensitivity. Ann Allergy 1986;57:135-7.
62. Warrington RJ, Martens CJ, Rubin M, et al. Immunologic studies in subjects with a serum sickness-like illness after immunization with human diploid cell rabies vaccine. J Allergy Clin Immunol 1987;79:605-61.
63. Swanson MC, Rosanoff E, Gurwith M, et al. IgE and IgG antibodies to β-propiolactone and human serum albumin associated with urticarial reactions to rabies vaccine. J Infect Dis 1987; 155:909-13.
64. Wilde H, Glueck R, Khawplod P, et al. Efficacy study of a new albumin-free human diploid cell rabies vaccine (Lyssavac-HDC, Bema) in 100 severely rabies-exposed Thai patients. Vaccine 1995;13:593-6.
65. Vermeer-de Bondt PE, Labadie J, Rümke HC. Rate of recurrent collapse after vaccination with whole cell pertussis vaccine: follow up study. BMJ 1998;316:902-3.
66. Tozzi AE, Ciofidegli Atti ML, Salmaso S, et al. Repeat whole cell vaccinations should be avoided after hypotonic-hyporesponsive episodes [letter]. BMJ 1998;317:604.
67. Centers for Disease Control and Prevention. Smallpox vaccine adverse events monitoring and response system for the first stage of the smallpox vaccination program. MMWR Morb Mortal Wkly Rep 2003;52:88-9, 99.